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Abstract
The presence of lymph node metastasis is a key prognostic factor in colorectal cancer and lymph node yield is an important
parameter in assessing the quality of histopathology reporting of colorectal cancer excision specimens. This study assesses
the trend in lymph node evaluation over time in a single institution and the relationship with the identification of lymph
node positive tumours. It compares the lymph node yield of a contemporary dataset compiled from the histopathology
reports of 2178 patients who underwent surgery for primary colorectal cancer between 2005 and 2012 with that of a
historic dataset compiled from the histopathology reports of 1038 patients who underwent surgery for colorectal cancer at
5 yearly intervals from 1975 to 2000. The mean lymph node yield was 14.91 in 2005 rising to 21.38 in 2012. In 2012 92.9% of
all cases had at least 12 lymph nodes examined. Comparison of the mean lymph node yield and proportion of Dukes C cases
shows a significant increase (Pearson correlation = 0.927, p = 0.001) in lymph node yield while there is no corresponding
significant trend in the proportion of Dukes C cases (Pearson correlation =20.138, p = 0.745). This study shows that there is
increasing yield of lymph nodes from colorectal cancer excision specimens. However, this is not necessarily associated with
an increase number of lymph node positive cancers. Further risk stratifying of colorectal cancer requires consideration of
other pathological parameters especially the presence of extramural venous invasion and relevant biomarkers.
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Introduction
Detection of metastasis in tumour-associated lymph nodes has a
highly significant effect on prognosis in patients with colorectal
cancer. All patients with one or more lymph nodes displaying
metastasis are upstaged to Dukes C/stage 3 disease. This has
important therapeutic consequences for a patient, as all these
patients are considered for treatment with adjuvant chemother-
apy. [1] Clinical trials including QUASAR, MOSAIC20 and
NSABP C-0721 trials have shown that adjuvant chemotherapy
with 5-fluorouracil alone enhances 5-year survival by around 5–
7% while a combination of 5-fluorouracil and oxaliplatin increases
5-year survival by 10–15% in stage 3 disease. [1–4] Consequently
according to current guidelines inadequate detection of positive
lymph nodes can lead to under treatment of lymph node positive
colorectal cancer.
It is generally considered and accepted that examining more
lymph nodes in a colorectal cancer excision specimen increases the
likelihood of identifying involved lymph nodes and thus upstaging
the cancer. However, recent studies have provided some contrary
evidence. Data collected from the National Cancer Institute’s
Surveillance, Epidemiology, and End Results (SEER) database for
86,394 patients showed that while the number of lymph nodes
being evaluated increased over time but that this did not
significantly increase the detection of node positive cancers. [5]
The study showed 34.5% of patients had 12 or more lymph nodes
evaluated between 1988–1990, compared to 73.6% of patients
between 2006 and 2008. However, the number of lymph node
positive cancers (Dukes C/stage 3) cancers detected did not
significantly increase between these time periods (40% node
positive cancers in 1988–1990 vs. 42% in 2006–2008 p= 0.53).
However, information was not consistently available in the SEER
database regarding the use of neoadjuvant therapy or participation
in a screening programme both factors which could influence
lymph node yield and tumour stage. Results from other centers are
similar and it has been suggested that suggest that examining more
than 12–17 lymph nodes may have a marginal effect on colorectal
cancer staging. [6]
These recent studies appear to contradict the hypothesis that
examining more lymph nodes increases the detection rate of node
positive disease. Nevertheless the studies by Parsons et al., [5], Bui
et al., [7] and Chang et al., [8] all show improved survival in
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patients when a higher number of lymph nodes are examined
compared to patients with fewer lymph nodes examined. This is
even seen for lymph node negative cancers. [5,8] These findings
suggest that factors other than upstaging may account for the
relationship between lymph node yield and survival. A simple
explanation is the tumor-host interaction. Patients who mount a
stronger immune response to their cancers may have larger
numbers of lymph nodes present and of greater size, making them
easier to find by pathologists. In addition to this, more extensive
surgical resection of the tumour’s lymphatic drainage system and
thus more complete node clearance may itself result in lower rates
of local or distant cancer recurrence. [9]
Despite the variation in the published evidence, guidance and
standards on lymph node yield have been introduced as a quality
performance indicator for the histopathology reporting of colo-
rectal cancer resections. Professional and regulatory bodies
including The Royal College of Pathologists UK, Healthcare
Improvement Scotland and American College of Pathologists have
recommended the identification of a minimum number of lymph
nodes from colorectal cancer resections as a standard and also as a
quality performance indicator. [10–12] The Royal College of
Pathologists UK recommends a minimum of 12 lymph nodes and
Healthcare Improvement Scotland guidance is for 80% of
colorectal cancer resections to have 12 or more lymph node
retrieved. [10,11]
This study assesses the trend in lymph node evaluation in a large
cohort of over a thirty seven year period in a single centre and
focuses on the trend in lymph node yield in comparison with the
proportion of lymph node positive cases.
Figure 1. Overview of the distribution of colorectal cancers in the contemporary dataset.
doi:10.1371/journal.pone.0104991.g001
Figure 2. Overview of the distribution of colorectal cancers in the historic dataset.
doi:10.1371/journal.pone.0104991.g002
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Table 1. Clinico-pathological parameters of the contemporary and historic colorectal cancer datasets.
Contemporary dataset (n =2178)
Historic dataset
(n =1038)
All cases (n =2178)
Non-neodjuvant therapy
(n =1748)
Neoadjuvant therapy
(n =430)
Gender
Male 54.9% (1195) 53.3% (931) 61.4% (264) 42.9% (445)
Female 45% (980) 46.6% (814) 38.6% 166 44.4.% (461)
Unknown 0.1% (3) 0.2% (3) - 12.8% (132)
Age
,71 51.2% (1114) 47.8% (836) 64.7% (278) 45.4% (471)
$71 48.7% (1061) 52% (909) 35.3% (152) 44.2% (459)
Unknown 0.1% (3) 0.2% (3) - 10.4% (108)
Tumour site
Proximal 41.1% (896) 50.6% (885) 2.6% (11) 43.3% (449)
Distal 31.4% (684) 38.5% (673) 2.6% (11) 30.1% (312)
Rectum 27.5% (598) 10.9% (190) 94.9% (408) 26.7% (277)
Tumour stage
T1 4.4% (96) 5.5% (96) - 2.4% (25)
T2 8.1% (176) 10.1% (176) - 9.5% (99)
T3 48.4% (1054) 60.3% (1054) - 80.2% (832)
T4 19.4% (422) 24.1% (422) - 7.9% (82)
yT0 4.5% (98) - 22.8% (98) -
yT1 2% (44) - 10.2% (44) -
yT2 4.2% (91) - 21.2% (91) -
yT3 8.1% (177) - 41.2% (177) -
yT4 0.9% (20) - 4.7% (20) -
Nodal stage
N0 43.9% (957) 54.7% (957) - 56.1% (582)
N1 22.5% (490) 28% (490) - 26.9% (279)
N2 13.8% (301) 17.2% (301) - 11.7% (121)
yN0 14.9% (325) - 75.6% (325) -
yN1 3.4% (74) - 17.2% (74) -
yN2 1.4% (31) - 7.2% (31) -
Nx - 5.4% (56)
Dukes stage
A 15.6% (339) 12.6% (221) 27.4% (118) 9.5% (99)
B 39.2% (853) 42.1% (736) 27.2% (117) 46.5% (483)
C 41.1% (895) 45.3 (791) 24.2% (104) 38.5% (400)
Not assessed1 - - - 5.4% (56)
Not determined2 4.1% (91) - 21.2% (91) -
Lymph node yield
,12nodes 18% (390) 17.4% (304) 20% (86) 28.3% (294)
$12 nodes 82% (1786) 82.6% (1444) 80% (344) 5.7% (59)
Not stated - 66% (685)
1. No lymph nodes assessed or no comment about lymph node positivity
2. Complete pathologic response (i.e. ypT0N0) to pre-operative neoadjuvant therapy.
doi:10.1371/journal.pone.0104991.t001
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Methods
Study population
This study included 3216 patients who had their colorectal
cancer pathology reported by the Department of Pathology,
Aberdeen Royal Infirmary from 1975–2012. The Department of
Pathology at Aberdeen Royal Infirmary is the regional pathology
centre serving three health authorities and four acute hospitals
namely NHS Grampian (Aberdeen Royal Infirmary; an academic
teaching hospital, Dr Grays’ Hospital, Elgin; a district general
hospital), NHS Orkney (Balfour Hospital, Kirkwall; remote and
rural hospital) and NHS Shetland (Gilbert Bain Hospital, Lerwick;
remote and rural hospital). Approximately 75% of the total
volume of colorectal cancer surgery is performed at Aberdeen
Royal Infirmary. Relevant pathological data was extracted from
the pathology reports of the resected colorectal cancer excision
specimens and two databases were constructed.
The first database was compiled using prospectively collected
histopathological data from colorectal cancers resected between
2005 and 2012. The information recorded in this database
includes age, gender, year of operation, administration of
neoadjuvant therapy, whether the tumour was screen detected,
tumour site, tumour differentiation, tumour (T) stage, extramural
venous invasion (EMVI), total number of lymph nodes examined,
number of lymph nodes involved by metastatic tumour, nodal (N)
stage and Dukes stage. Information for each parameter was
available for every patient. This database is referred to as the
contemporary dataset and the distribution of cases in this series is
shown in figure 1. The histopathology of all the cases in this
database were reported according to the criteria of the Royal
College of Pathologists UK [10] for the reporting of colorectal
cancer excision specimens and all these cases were subject to
multi-disciplinary review. Throughout this period of time NHS
Grampian has been a centre for the NHS Scotland bowel
screening programme (2000–2006, pilot centre for evaluation of
programme, 2007-part of national programme following its
implementation throughout Scotland).
The second database was compiled retrospectively from cases of
colorectal cancers identified by searching the Department of
Pathology computer database using the search terms ‘colon’,
‘rectum’ and ‘carcinoma’. Histopathology reports of colorectal
cancers excised at 5 yearly intervals 1975, 1980, 1985, 1990, 1995
and 2000 were identified and reviewed. Information on patient
age and gender, tumour site, tumour differentiation, T stage, N
stage, total number of lymph nodes examined, total number of
lymph nodes involved and Dukes stage were extracted from these
reports (when stated) and used to assemble the database. When not
explicitly stated Dukes stage was inferred from the information
stated in the histopathology report regarding the depth of tumour
invasion and lymph node involvement. This database is referred to
as the historic dataset and the distribution of cases is shown in
figure 2.
Statistics
Both databases were compiled in Excel 2007 and then imported
into IBM SPSS version 21 for Windows 7TM (IBM, Portsmouth,
UK) to perform data analysis. Linear trends for changes in lymph
node yield and proportion of Dukes C cases with time were
determined using Excel 2007 (Microsoft, Seattle, USA).
Ethics
The project was carried out using anonymised data and within
the remit of ethics approval (ref. nos. 08/S0801/81) from the
North of Scotland research ethics committee.
Results
The clinico-pathological parameters collected for the contem-
porary and historic datasets are summarised in table 1. Informa-
tion for all parameters was complete for the contemporary
database where as significant proportion of pathology reports in
the historic dataset had no information documented on gender
(12.8%), age (10.4%), number of lymph nodes retrieved (66%) and
number of lymph nodes involved by metastatic tumour (66.6%).
Pathology reports in the historic dataset often made descriptive
comments about the extent of tumour invasion from which
tumour stage could be inferred and similarly about lymph node
involvement from which Dukes stage could be inferred.
The lymph node yield in the contemporary series of colorectal
cancers is summarised in table 2 and in detail in table 3. Mean
lymph node yield increased from 14.91 in 2005 to 21.38 in 2012
and the proportion of cases with 12 or more lymph nodes
Table 2. Lymph node yield for all colorectal cancers 2005–2012.
Mean lymph node
yield
Percentage (number) of cases with $12
lymph nodes
All colorectal cancer cases (n = 2178) 17.4 82% (1786)
Cases which did not receive neo-adjuvant therapy
(n = 1748)
17.66 82.6% (1442)
Cases which received neoadjuvant therapy (n = 430) 16.34 80% (344)
Colon cancer (n = 1580) 17.46 81.8% (1292)
Proximal (n = 896) 18.28 85.7% (769)
Distal (n = 684) 16.27 76.6% (523)
Rectal cancers (n = 598) 17.24 82.8% (495)
Cases which did not receive neoadjuvant therapy
(n = 190)
19.24 90% (171)
Cases which received neoadjuvant therapy (n = 408) 16.32 79.4% (324)
doi:10.1371/journal.pone.0104991.t002
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increased from 69.4% of cases in 2005 to 92.9% of cases in 2012.
Mean lymph node yield is significantly less in the group that had
received neoadjuvant therapy prior to surgery compared to those
patient who did not receive any such therapy (p,0.001, Mann
Whitney U test). Mean lymph node yield is also less in distal colon
cancers compared with proximal colon cancers (p,0.001, Mann
Whitney U test).
The frequency distribution of tumour stage in both the historic
dataset and the contemporary dataset is shown in figure 3 and in
detail in table 4. Data is shown only for colon cancers with both
screen detected cases and rectal cancers excluded to allow direct
comparison of the historic cases with the contemporary cases. The
mean frequency of Dukes C cases in the historic dataset is 36.53%
of cases while the mean frequency of Dukes C cases in the
contemporary dataset is 47.9% of cases. The frequency distribu-
tion of Dukes stages per year in the contemporary dataset is shown
in figure 4 and illustrates for all cases (figure 4A), cases which did
not receive neoadjuvant therapy (figure 4B), colon cancers
(figure 4C) and symptomatic colon cancers (i.e. bowel cancer
screening detected cases excluded, figure 4D).
In the contemporary data set comparison of mean lymph node
yield and proportion of Dukes C cases shows a highly significant
year on year increase (Pearson correlation= 0.927, p = 0.001) in
lymph node yield in contrast there is no significant trend in Dukes
cases (Pearson correlation=20.138, p= 0.745). This is true both
for all colorectal cancers and also when potential confounding
factors are excluded from the analysis including administration of
neoadjuvant therapy, bowel cancer screening detected cases
(Figure 5). Figure 5d shows the trends in lymph node yield in
Dukes C cases and mean lymph node yield in colon cancer with
those confounding factors excluded from the analysis there
remains a significant upward trend in mean lymph node yield
(Pearson correlation= 0.884, p = 0.004) while there is a non-
significant trend towards a lower proportion of Dukes C cases
(Pearson correlation=20.300, p = 0.470).
Discussion
This large study from a single centre assesses the trend in lymph
node evaluation over a thirty seven year period. It utilises both a
contemporary dataset and a historic dataset to compare the effect
of time and recent advances in colorectal cancer treatment,
screening and pathological reporting on lymph node yield and
involvement. It examines in detail the effect lymph node yield has
on the detection of lymph node positive disease and hence
colorectal cancer staging. All the data has been compiled from one
centre thus minimising potential data collection and reporting
bias.
Factors that influence lymph node yield include patient, surgeon
oncologist and pathologist and in designing this study it was
important to consider key confounding factors to allow meaningful
comparison of data especially between the historic dataset and the
contemporary dataset. [10–12] The major changes in colorectal
cancer diagnosis and management that have occurred and have
been considered are the introduction of bowel cancer screening
and the use of neoadjuvant therapy as standard therapy for rectal
cancer judged at high risk of local recurrence. NHS Grampian was
a pilot site for assessment of the bowel cancer screening
programme from 2000–2006 prior to the Scottish wide introduc-
tion of this programme in 2007. The introduction and widespread
adoption of neoadjuvant therapy as standard therapy for rectal
cancers judged at high risk of local recurrence (using thin slice
MRI) was the standard of care in this region by 2005. Bowel
cancer screening has the potential to alter the stage distribution of
colorectal cancer with the detection of more early stage tumours
while neoadjuvant therapy for rectal cancer would be expected to
alter stage distribution and also potentially reduce lymph node
yield. [13–18] Information regarding both these factors was
available for patients in the contemporary dataset and both these
factors have been explicitly considered in the analysis of the data.
There is also the expectation that in a well screened population
over time there should be a reduction in the number of lymph
node positive colorectal cancers. This explanation for the changes
Figure 3. The frequency of individual tumour stages in colon cancer from 1975–2012. The 2005–2012 data excludes screen detected
cancers thus allowing direct comparison with the historic data set prior to the introduction of the bowel cancer screening programme. Rectal cancers
have also been excluded as the introduction of neo-adjuvant therapy for rectal cancers excludes the direct comparability of rectal cancer staging.
doi:10.1371/journal.pone.0104991.g003
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in the frequency of Dukes C cancer is thought to be unlikely as the
bowel screening programme has probably not been implemented
for a long enough time period nor during that period has,
unfortunately, there been sufficient population participation in the
programme. [19]
Histopathological reporting of colorectal cancers has greatly
improved over the last 15 years driven by the introduction of
guidelines and datasets for the reporting of colorectal cancer
excision specimens and the parallel requirement for high quality
pathology reporting as adjuvant and neoadjuvant therapy became
recognized and established therapeutic options in the treatment of
colorectal cancer. [1,10] It is also important to have well
characterised colorectal cancer datasets for translational research
e.g. colorectal cancer biomarker research. [20–22]
One of the key quality parameter in colorectal cancer
histopathology is lymph node yield. The current Royal College
of Pathologists UK colorectal cancer dataset recommends a mean
of 12 lymph nodes and Healthcare Improvement Scotland quality
performance indicator for colorectal cancer pathology is that
greater than 80% of colorectal cancers should have 12 or more
lymph nodes identified. [10,11] However, in both guidelines it is
either explicitly stated or implied that it is essential to identity all
lymph nodes. The rationale for this guidance is that it is assumed
that increasing the yield of lymph nodes will increase the
proportion of lymph node positive cases being identified. However
studies have suggested that this may not be the case and also the
identification of what could be described as low volume metastatic
disease has led to the development of lymph node ratio as a
concept and therapeutic decision making criterion (currently
subject of separate ongoing study in this patient population). [23–
30]
Our data from the historic database shows that from 1975 to
2000 there is a higher proportion of Dukes B tumours and a lower
proportion of Dukes C tumours compared to the tumours excised
between 2005 and 2012 and this reflects the low lymph node yield
per case and supports the concept of understaging of colorectal
cancers when there is a low yield of lymph nodes. However in the
current data set while there is a significant trend to increase lymph
node yield this has not been reflected in an increasing proportion
of Dukes C cases even when the confounding factors of
neoadjuvant therapy and bowel cancer screen detected cases have
been excluded from the analysis. The reasons for this are not
apparent and have been observed in other series. Age distribution
and anatomical site distribution of tumours within the colon both
of which are other potential confounding factors do not appear to
have significantly altered with time. Over the period of time from
2005–2012 pre-operative staging protocols have also remained
constant. This may suggest that there may be a threshold for
lymph node yield above which there is marginal benefit in
identifying further lymph nodes. [31] Nonetheless at the practical
level there is still strong justification for ensuring all lymph nodes
are identified in a colorectal cancer excision specimen. Lymph
node yield is a valuable quality parameter for both pathology and
surgery and a low lymph node yield appears to be associated with
poorer prognosis. [32] Any use of lymph node ratio as a prognostic
factor is also predicated on optimal identification of both all
Figure 4. The tumour stage frequency distribution of colorectal cancer 2005–2012. A. All colorectal cancers, B. cases that did not receive
neoadjuvant therapy, C. colon cancers, D. colon cancers excluding bowel screening detected cases.
doi:10.1371/journal.pone.0104991.g004
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involved lymph nodes and the total number of lymph nodes.
However, it also suggests that other prognostic markers need to be
considered and given more significance in the decision making
process of colorectal cancer treatment including the design of
future clinical trials. These include other known prognostic
parameters especially extramural venous invasion, further studies
of ratio of involved to total lymph nodes and the selective use of
validated prognostic biomarkers. [33]
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